Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin and Nirogacestat in Relapsed/Refractory Multiple Myeloma (DREAMM5 Sub-study 3)
NCT07084896Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of belantamab mafodotin, nirogacestat in multiple myeloma (MM), sponsored by GSK. Started Jun 2020; status: active, not recruiting.
02
Drugs
belantamab mafodotinnirogacestat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07084896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084896.